MedTrace Logo

A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)

NCT04433585 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 291

Last updated 2024-04-23

Study results available
· View outcomes & findings →

Summary

The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and effective in adults with systemic lupus erythematosus (SLE).

Conditions

Interventions

DRUG

LY3471851

Administered SC

DRUG

Placebo

Administered SC

Sponsors & Collaborators

Principal Investigators

  • Study Director · Nektar Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-19
Primary Completion
2023-01-10
Completion
2023-02-16
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Canada
  • Czechia
  • Germany
  • Hungary
  • India
  • Israel
  • Japan
  • Mexico
  • Poland
  • Puerto Rico
  • Romania
  • Russia
  • South Korea
  • Spain
  • Taiwan
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04433585 on ClinicalTrials.gov